| Drug General Information |
| Drug ID |
D09JCF
|
| Former ID |
DNC004867
|
| Drug Name |
Huprine-Tacrine Heterodimer
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Cholinesterase |
Target Info |
Inhibitor |
[1]
|
|---|
| Acetylcholinesterase |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Glycerophospholipid metabolism
|
|
Cholinergic synapse
|
|
PANTHER Pathway
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
Muscarinic acetylcholine receptor 2 and 4 signaling pathway
|
|
Nicotinic acetylcholine receptor signaling pathwayP00042:Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
Nicotinic acetylcholine receptor signaling pathway
|
|
Pathway Interaction Database
|
ATF-2 transcription factor network
|
|
PathWhiz Pathway
|
Phospholipid Biosynthesis
|
|
WikiPathways
|
Irinotecan PathwayWP727:Monoamine Transport
|
|
Biogenic Amine Synthesis
|
|
Acetylcholine Synthesis
|
|
Integrated Pancreatic Cancer Pathway
|
| References |
| REF 1 | J Med Chem. 2005 Mar 24;48(6):1701-4.Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. |
|---|
